Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 2/20 | 0.73 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.73 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.73 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.73 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.73 |
| ▸ | GABRP | O00591 | 4/20 | 0.69 |
| ▸ | GABRD | O14764 | 4/20 | 0.69 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.69 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.69 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.69 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.69 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.69 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.69 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.69 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.69 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.69 |
| ▸ | GABRE | P78334 | 4/20 | 0.69 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.69 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.69 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7979058 | 1.00 | GRIN1 (0.73) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL12178039 | 1.00 | GRIN1 (0.73) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL16937805 | 1.00 | GRIN1 (0.73) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL643029 | 1.00 | GRIN1 (0.73) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL2980777 | 1.00 | GRIN1 (0.73) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL2589576 | 1.00 | GRIN1 (0.73) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL2981380 | 1.00 | GRIN1 (0.73) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL19733059 | 1.00 | GRIN1 (0.73) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL22449551 | 1.00 | GRIN1 (0.73) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL24022389 | 0.93 | MAPK1 (0.64) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20220395513-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220162255-A1 | PROCESS FOR PREPARING HIGH PURITY ALLOPREGNANOLONE AND INTERMEDIATES THEREOF | CURIA SPAIN, S.A.U. (ES) | 2022-05-26 | — | — | US | disclosed |
| EP-3941925-A1 | PROCESS FOR PREPARING HIGH PURITIY ALLOPREGNANOLONE AND INTERMEDIATES THEREOF | Crystal Pharma, S.A.U. (ES) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020187965-A1 | PROCESS FOR PREPARING HIGH PURITIY ALLOPREGNANOLONE AND INTERMEDIATES THEREOF | BIONICE, S.L.U. (ES) | 2020-09-24 | — | — | WO | disclosed |
| US-20200299323-A1 | PROCESS FOR PREPARING HIGH PURITIY ALLOPREGNANOLONE AND INTERMEDIATES THEREOF | CURIA SPAIN, S.A.U. (ES) | 2020-09-24 | — | — | US | disclosed |
| EP-3712161-A1 | PROCESS FOR PREPARING HIGH PURITIY ALLOPREGNANOLONE AND INTERMEDIATES THEREOF | Bionice, S.L.U. (ES) | 2020-09-23 | — | — | EP | disclosed |
| US-8759330-B2 | Neuroactive 13,24-cyclo-18,21-dinorcholanes and structurally related pentacylic steroids | WASHINGTON UNIVERSITY (US) | 2014-06-24 | — | — | US | disclosed |
| US-20100317638-A1 | Neuroactive 13,24-Cyclo-18,21-Dinorcholanes and Structurally Related Pentacylic Steroids | WASHINGTON UNIVERSITY (US) | 2010-12-16 | — | — | US | disclosed |
| US-7781421-B2 | Neuroactive 13, 24-cyclo-18, 21-dinorcholanes and structurally related pentacyclic steriods | WASHINGTON UNIVERSITY (US) | 2010-08-24 | — | — | US | disclosed |
| EP-1626980-A4 | NEUROACTIVE 13,24-CYCLO-18,21-DINORCHOLANES AND STRUCTURALLY-RELATED PENTACYCLIC STEROIDS | UNIV WASHINGTON (US) | 2007-07-04 | — | — | EP | disclosed |
| EP-1626980-A1 | NEUROACTIVE 13,24-CYCLO-18,21-DINORCHOLANES AND STRUCTURALLY-RELATED PENTACYCLIC STEROIDS | WASHINGTON UNIVERSITY (US) | 2006-02-22 | — | — | EP | disclosed |
| WO-2005000869-A1 | NEUROACTIVE 13,24-CYCLO-18,21-DINORCHOLANES AND STRUCTURALLY-RELATED PENTACYCLIC STEROIDS | WASHINGTON UNIVERSITY (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040242549-A1 | Neuroactive 13, 24-cyclo-18, 21-dinorcholanes and structurally related pentacyclic steroids | WASHINGTON UNIVERSITY | 2004-12-02 | — | — | US | disclosed |
| EP-0554436-B1 | GABA RECEPTOR MODULATORS | EURO CELTIQUE SA (LU) | 2000-07-05 | — | — | EP | disclosed |
| US-5591733-A | TREATMENT OF ANXIETY, STRESS, INSOMNIA, SEIZURES, STEROIDS, ACTIVE AT GAMMA-AMINOBUTYRIC ACID RECEPTORS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1997-01-07 | — | — | US | disclosed |
| EP-0554436-A4 | — | — | 1994-01-12 | — | — | EP | disclosed |
| EP-0554436-A1 | GABA RECEPTOR MODULATORS | COCENSYS, INC. (US) | 1993-08-11 | — | — | EP | disclosed |
| US-5232917-A | Tranquillizers; antianxiolytic agents; sedatives; antidepressants; anticonvulsants; neurotransmitters | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1993-08-03 | — | — | US | disclosed |
| WO-1993003732-A1 | GABA RECEPTOR MODULATORS | COCENSYS, INC. (US) | 1993-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | CYP21A2, CYP46A1, CYP17A1 | GRIN1 2519/4885GRIN2B 2012/4885GRIN2D 3231/4885 |
| US-20200299323-A1 | PROCESS FOR PREPARING HIGH PURITIY ALLOPREGNANOLONE AND INTERMEDIATES THEREOF | CYP21A2, CYP17A1, CYP11B1 | GRIN1 791/4885GRIN2B 621/4885GRIN2D 938/4885 |
| US-20220395513-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | CYP21A2, CYP46A1, CYP17A1 | GRIN1 2519/4885GRIN2B 2012/4885GRIN2D 3231/4885 |
| US-20100317638-A1 | Neuroactive 13,24-Cyclo-18,21-Dinorcholanes and Structurally Related Pentacylic Steroids | HSD17B13, GABRD, HSD17B3 | GRIN1 124/4885GRIN2B 111/4885GRIN2D 140/4885 |
| US-20220162255-A1 | PROCESS FOR PREPARING HIGH PURITY ALLOPREGNANOLONE AND INTERMEDIATES THEREOF | CYP17A1, CYP21A2, CYP11B1 | GRIN1 748/4885GRIN2B 646/4885GRIN2D 875/4885 |
| US-20040242549-A1 | Neuroactive 13, 24-cyclo-18, 21-dinorcholanes and structurally related pentacyclic steroids | HSD17B13, GABRD, HSD17B3 | GRIN1 127/4885GRIN2B 112/4885GRIN2D 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.